propafenone has been researched along with Cardiac Failure in 12 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Propafenone is an effective drug for the management of ventricular tachyarrhythmias, and may be used in patients with impaired left ventricular function." | 5.27 | Propafenone therapy for ventricular tachycardia in the setting of congestive heart failure. ( Abate, D; Allen, BJ; Brodsky, MA; Henry, WL, 1985) |
| "In-hospital administration of flecainide and propafenone in a single oral loading dose has been shown to be effective and superior to placebo in terminating atrial fibrillation." | 5.11 | Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. ( Alboni, P; Baldi, N; Baroffio, R; Botto, GL; Calzolari, M; Gaggioli, G; Gianfranchi, L; Luzi, M; Marchi, P; Russo, V; Solano, A, 2004) |
| " The abilities of TAEA and ISQ-1 to terminate AF, with comparison to the rapidly activating component of delayed rectifier potassium current blocker (+)-N-[1'-(6-cyano-1,2,3,4-tetrahydro-2(R)-naphthalenyl)-3,4-dihydro-4(R)-hydroxyspiro(2H-1-benzopyran-2,4'-piperidin)-6-yl]methanesulfonamide] monohydrochloride (MK-499) and the class IC 1-[2-[2-hydroxy-3-(propylamino)-propoxy]phenyl]-3-phenyl-1-propanone (propafenone), were assessed in conscious dogs with heart failure and inducible AF (entry criterion)." | 3.74 | Atrial antifibrillatory effects of structurally distinct IKur blockers 3-[(dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in dogs with underlying heart failure. ( Beshore, DC; Dinsmore, CJ; Kiss, L; Liverton, NJ; Lynch, JJ; McIntyre, CJ; Regan, CP; Stump, GL, 2008) |
| "The incidence of drug-induced congestive heart failure with several newer antiarrhythmic agents including encainide, ethmozine, lorcainide, mexiletine, propafenone and tocainide was determined in a group of 407 patients who underwent 1,133 drug tests." | 3.67 | Congestive heart failure induced by six of the newer antiarrhythmic drugs. ( Lampert, S; Lown, B; Podrid, PJ; Ravid, S, 1989) |
| "Propafenone is an effective drug for preventing supraventricular tachyarrhythmia, but the incidence of side effects during longterm therapy in patients with such arrhythmias has not been adequately reported." | 2.68 | Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group. ( Anderson, JL; Podrid, PJ, 1996) |
| "Amiodarone has been demonstrated to be more efficacious than propafenone or sotalol in the Canadian Trial of Atrial Fibrillation." | 2.42 | Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. ( Bhatta, L; Hynes, J; Khan, M; Luck, J; Naccarelli, GV; Samii, S; Wolbrette, DL, 2003) |
| "Antiarrhythmic drugs may induce congestive heart failure in patients with malignant ventricular arrhythmias and depressed left ventricular (LV) function." | 1.28 | Changes in cardiac output determined by continuous-wave Doppler echocardiography during propafenone or mexiletine drug testing. ( Lampert, S; Lange, H; Lown, B; Sutton, MS, 1990) |
| "The effects of orally administered propafenone on ejection fraction (EF) determined by radionuclide angiography were studied in 2 groups of patients receiving different dosing regimens." | 1.27 | Effect of propafenone on left ventricular ejection fraction. ( Baker, BJ; de Soyza, ND; Dinh, H; Franciosa, JA; Kroskey, D; Murphy, ML, 1984) |
| "Propafenone is an effective drug for the management of ventricular tachyarrhythmias, and may be used in patients with impaired left ventricular function." | 1.27 | Propafenone therapy for ventricular tachycardia in the setting of congestive heart failure. ( Abate, D; Allen, BJ; Brodsky, MA; Henry, WL, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (33.33) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Wybraniec, MT | 1 |
| Kampka, Z | 1 |
| Mizia-Stec, K | 1 |
| Lip, GY | 1 |
| Fauchier, L | 1 |
| Freedman, SB | 1 |
| Van Gelder, I | 1 |
| Natale, A | 1 |
| Gianni, C | 1 |
| Nattel, S | 1 |
| Potpara, T | 1 |
| Rienstra, M | 1 |
| Tse, HF | 1 |
| Lane, DA | 1 |
| Naccarelli, GV | 1 |
| Wolbrette, DL | 1 |
| Khan, M | 1 |
| Bhatta, L | 1 |
| Hynes, J | 1 |
| Samii, S | 1 |
| Luck, J | 1 |
| Alboni, P | 1 |
| Botto, GL | 1 |
| Baldi, N | 1 |
| Luzi, M | 1 |
| Russo, V | 1 |
| Gianfranchi, L | 1 |
| Marchi, P | 1 |
| Calzolari, M | 1 |
| Solano, A | 1 |
| Baroffio, R | 1 |
| Gaggioli, G | 1 |
| Regan, CP | 1 |
| Kiss, L | 1 |
| Stump, GL | 1 |
| McIntyre, CJ | 1 |
| Beshore, DC | 1 |
| Liverton, NJ | 1 |
| Dinsmore, CJ | 1 |
| Lynch, JJ | 1 |
| Baker, BJ | 1 |
| Dinh, H | 1 |
| Kroskey, D | 1 |
| de Soyza, ND | 1 |
| Murphy, ML | 1 |
| Franciosa, JA | 1 |
| Podrid, PJ | 2 |
| Anderson, JL | 1 |
| SoRelle, R | 1 |
| Lange, H | 1 |
| Lampert, S | 2 |
| Sutton, MS | 1 |
| Lown, B | 2 |
| Ravid, S | 1 |
| Sbirrazzuoli, V | 1 |
| Lapalus, P | 1 |
| Brodsky, MA | 1 |
| Allen, BJ | 1 |
| Abate, D | 1 |
| Henry, WL | 1 |
3 reviews available for propafenone and Cardiac Failure
| Article | Year |
|---|---|
Pharmacological cardioversion of atrial fibrillation: practical considerations.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Heart Diseases; Heart Failure; H | 2023 |
Atrial fibrillation.
Topics: Ablation Techniques; Anticoagulants; Aspirin; Atrial Fibrillation; Dizziness; Dyspnea; Electric Coun | 2016 |
Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Australia; Canada; Controlled Clinical Tria | 2003 |
2 trials available for propafenone and Cardiac Failure
| Article | Year |
|---|---|
Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach.
Topics: Administration, Oral; Ambulatory Care; Anti-Arrhythmia Agents; Atrial Fibrillation; Feasibility Stud | 2004 |
Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group.
Topics: Administration, Oral; Adult; Age Factors; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial | 1996 |
7 other studies available for propafenone and Cardiac Failure
| Article | Year |
|---|---|
Atrial antifibrillatory effects of structurally distinct IKur blockers 3-[(dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in dogs with underlying heart failure.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzopyrans; Cell Line; Dogs; Female; Heart At | 2008 |
Effect of propafenone on left ventricular ejection fraction.
Topics: Aged; Anti-Arrhythmia Agents; Cardiac Output; Digoxin; Heart; Heart Failure; Humans; Male; Middle Ag | 1984 |
Late-breaking clinical trials at the American Heart Association's scientific sessions 2001.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Coronary Artery Bypass; Coron | 2001 |
Changes in cardiac output determined by continuous-wave Doppler echocardiography during propafenone or mexiletine drug testing.
Topics: Cardiac Output; Depression, Chemical; Echocardiography, Doppler; Female; Heart Failure; Humans; Male | 1990 |
Congestive heart failure induced by six of the newer antiarrhythmic drugs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Anti-Arrhythmia Agents; Benzeneacetamides; Enc | 1989 |
Human lymphocyte and myocardial beta-adrenoceptors: up and down regulation.
Topics: Down-Regulation; Female; Heart Failure; Humans; Lymphocytes; Male; Middle Aged; Myocardium; Propafen | 1989 |
Propafenone therapy for ventricular tachycardia in the setting of congestive heart failure.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Electrocardiography; Electrophysiology; E | 1985 |